32 results
8-K
EX-99.1
IKT
Inhibikase Therapeutics Inc
30 Apr 24
Regulation FD Disclosure
8:17am
-001Pro for Treatment of Blood and Stomach Cancers and Cardiopulmonary Disease Inhibikase.com : IKT 17
IkT- 001Pro INNOVATION IkT-001Pro releases
424B3
6kh8p4
4 Apr 23
Prospectus supplement
4:57pm
POS AM
gsmlzb1t
31 Mar 23
Prospectus update (post-effective amendment)
4:11pm
PRE 14A
cujb3lm25d26vct
21 Apr 22
Preliminary proxy
4:33pm
8-K
EX-99.1
e3f6pftlvll4ojpirwp0
20 Jan 22
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 1Q 2022 BUSINESS PRESENTATION IKT
4:10pm
8-K
EX-99.1
atb5g7wlg
19 Oct 21
Clinical Development of Therapies Intended to Reverse the Functional Loss in Parkinson’s and Related Disorders 4Q 2021 BUSINESS PRESENTATION IKT
5:03pm
8-K
EX-99.1
a2nywz3mbgri
17 Aug 21
Regulation FD Disclosure
5:02pm
424B4
cbx8 31958l
17 Jun 21
Prospectus supplement with pricing info
4:31pm
DRS
a1ra2g6
2 Jun 21
Draft registration statement
12:00am
8-K
EX-99.1
vbldf0fvd gt7
1 Jun 21
Regulation FD Disclosure
7:30am
DEF 14A
rnv7cs
30 Apr 21
Definitive proxy
5:20pm